Karolinska Development: Our View on Missed Top-Line Results in the Aprea Holding

Research Note

2020-12-29

08:30

Redeye recognizes the Aprea Therapeutics (Aprea) phase 3 top-line results as a miss and disappointing. Even though the top-line result is not a clear miss and will entail further analysis on the full dataset, the some -80% stock reaction in Aprea has a major impact on Karolinska Development (KD). We update our Fair Values with immediate effect.

AH

Anders Hedlund

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.